Key Highlights

  • Micro-X (ASX:MX1) shares gained 2.56% to A$0.040 on June 3, 2026.
  • The company captured its first human patient images using the Head CT scanner.
  • The imaging study is being conducted at the Royal Melbourne Hospital.
  • A second Head CT test bench has been completed for deployment at the Royal Adelaide Hospital.
  • Completion of project milestones will trigger a A$0.4 million payment to the company.

Micro-X (ASX:MX1) shares edged higher on June 3, rising 2.56% to A$0.040 after the medical imaging technology company announced a significant milestone in the development of its Head CT scanner. The company revealed that the first human patient images had been acquired using its carbon nanotube (CNT) cone beam computed tomography technology, marking the start of a multi-centre clinical pilot study.

The stock traded between A$0.038 and A$0.040 during the session as investors assessed the implications of the latest development for the company's healthcare imaging platform and future regulatory pathway.

First Human Imaging Achieved

The headline announcement centred on the successful Acquisition of human patient images using Micro-X's Head CT scanner at the Royal Melbourne Hospital.

According to the company, the images represent the first human imaging conducted using its curved-array CNT cone beam CT technology. The resulting data will be used to refine image reconstruction algorithms as part of the initial phase of a broader clinical evaluation program.

Management described the achievement as a major technical milestone following several years of development work focused on miniaturised medical imaging technology.

The commencement of human imaging also marks a transition from technology development and testing toward clinical validation in real-world healthcare settings.

Multi-Centre Clinical Study Underway

The pilot study has been designed as a comparative investigation evaluating image quality against conventional CT imaging.

Researchers will assess whether images generated by the Micro-X system can identify brain imaging-based contraindications to stroke thrombolysis. The study will involve patients presenting with a range of neurological conditions, including ischaemic stroke, intracranial haemorrhage, brain tumours and stroke mimic conditions.

The project aims to enrol 108 patients, with imaging expected to continue over approximately six to nine months to ensure a representative sample of clinical cases.

Radiographers at the Royal Melbourne Hospital have been trained to operate the system, while the Australian Stroke Alliance research team will analyse the imaging results following completion of the study.

The findings are expected to contribute to future decisions regarding product development and regulatory planning.

Second Trial Site Reaches Key Milestone

Alongside the commencement of human imaging, Micro-X announced the completion of a second Head CT test bench for deployment at the Royal Adelaide Hospital.

The company stated that Manufacturing, safety testing and verification activities have now been completed, satisfying key milestones under its Medical Research Future Fund collaboration with the Australian Stroke Alliance.

Completion of these milestones is expected to trigger a payment of A$0.4 million to Micro-X.

The establishment of a second trial site expands the company's clinical evaluation capabilities and supports the broader objectives of the pilot study.

Focus on Portable Stroke Imaging

The Head CT scanner is being developed to support rapid clinical decision-making in acute stroke care.

Unlike conventional CT systems, the future device is intended to be compact enough for deployment in environments outside traditional radiology departments. The company is designing the system to fit within a standard road ambulance while maintaining the ability to generate three-dimensional brain images.

The technology uses a curved array of 21 electronically controlled carbon nanotube X-ray tubes combined with proprietary image reconstruction software.

Micro-X believes the system could eventually support faster access to diagnostic imaging, particularly in emergency and pre-hospital settings where rapid stroke assessment may influence treatment decisions.

Government and Research Support

The Head CT development program has attracted significant support from government and research organisations.

The project has received funding from the Australian Government's Medical Research Future Fund, while further development is being supported through an Industry Growth Program grant.

The initiative also involves collaboration with the Australian Stroke Alliance, Monash University's Design Health Collab and Johns Hopkins University.

These partnerships provide access to clinical expertise, research infrastructure and technical support as the project progresses through development and validation stages.

Market Focus Turns to Clinical Outcomes

While the commencement of human imaging represents a notable technical achievement, investors are likely to focus on future study outcomes and the company's progress toward regulatory approval pathways.

The clinical data generated through the pilot study is expected to play an important role in demonstrating image quality, clinical Utility and system performance.

As patient enrolment progresses over the coming months, the market will be watching for updates regarding image analysis, trial completion and future commercialisation plans.

About the Company

Micro-X (ASX:MX1) is an Australian medical imaging technology company specialising in carbon nanotube-based X-ray systems. The company develops imaging solutions for healthcare and security applications, with a focus on miniaturised and portable imaging technologies.

Industry Trends and Market Context

Medical imaging companies continue to invest in technologies that improve portability, accessibility and efficiency of diagnostic systems. Healthcare providers are increasingly exploring imaging solutions that can support faster diagnosis while reducing logistical barriers associated with conventional equipment.

In stroke care, there is growing interest in technologies capable of bringing imaging closer to patients, particularly in emergency and remote settings. Advances in miniaturisation, image processing and digital health integration are shaping the next generation of diagnostic imaging devices.

Bullish Perspective

Investors with a positive outlook may view the commencement of human imaging as evidence that the Head CT project is progressing from development into clinical validation. The generation of patient data, expansion to multiple trial sites and continued funding support could be seen as important steps toward future regulatory and commercial milestones.

Bearish Perspective

A more cautious perspective recognises that the technology remains under clinical evaluation. Regulatory approval, broader clinical adoption and commercial deployment remain future objectives, and the pilot study results may not necessarily confirm the anticipated clinical utility or performance of the system.

Investment Risks and Challenges

Micro-X faces risks associated with medical device development, including clinical trial outcomes, regulatory approvals and commercial adoption. Delays in validation studies, technical challenges or changes in healthcare purchasing priorities could affect development timelines. The company also remains exposed to funding requirements, competitive technologies and the complexities associated with bringing new medical imaging platforms to market.